Navigation Links
Statement from ASH President Armand Keating, M.D., on FDA action to alleviate drug shortages
Date:2/21/2012

(WASHINGTON, February 21, 2012) The American Society of Hematology (ASH) is encouraged by the steps FDA is taking to alleviate drug shortages that have significantly affected so many patients with hematologic malignancies under our members' care. The measures announced today are consistent with the Society's recommendations to FDA, Congress, and the Obama Administration to expand the agency's authority to prevent drug shortages by requiring manufacturers to provide early notification of impending shortages and importing drugs in critical supply.

While ASH applauds the specific actions announced today, we also realize that these measures represent only a portion of a solution to a much larger problem. In addition to these steps, additional measures - such as developing a national drug registry and providing economic incentives to manufacturers to produce a steady supply of generics - must be implemented to permanently prevent shortages. Until a complete solution is in place, treatment will be delayed and care will be rationed for critically ill patients. ASH will continue to support legislative, regulatory, and policy changes that will give FDA the ability to prevent and mitigate drug shortages before they progress to crisis status.


'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
202-552-4927
American Society of Hematology
Source:Eurekalert

Page: 1

Related medicine news :

1. American Society of Hematology statement on critical methotrexate drug shortage
2. ATS issues joint statement on key issues and recommendations for critical care research
3. ACR and SBI issue statement on British Medical Journal article on effect of mammography on breast cancer death rates
4. EMAS publishes position statement about the post-reproductive health of women
5. AMP releases statement on diagnostics in drug labels
6. Radiation risks to health: A joint statement from leading scientific experts
7. ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis
8. ATS issues statement on the treatment of pulmonary fungal infections
9. IOF statement on new IOM dietary reference intakes for calcium and vitamin D
10. EMAS publishes position statements about the post-reproductive health of women
11. AAO-HNS releases consensus statement: diagnosis and management of nasal valve compromise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: